1-Boc-7-氮杂吲哚 | 138343-77-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并吡啶类
• 中文名称: 1-Boc-7-氮杂吲哚
• 中文别名: 7-氮杂吲哚-1-甲酸叔丁酯；N-Boc-7-氮杂吲哚
• 英文名称: tert-butyl 1H-pyrrolo[2,3-b]pyridine-1-carboxylate
• 英文别名: N-boc-7-azaindole；1-Boc-7-azaindole；tert-butyl pyrrolo[2,3-b]pyridine-1-carboxylate
• CAS: 138343-77-8
• 化学式: C₁₂H₁₄N₂O₂
• mdl: MFCD08272245
• 分子量: 218.255
• InChiKey: SGZMGGUBXZBVPJ-UHFFFAOYSA-N

物化性质

• 沸点：
  327.2±34.0 °C(Predicted)
• 密度：
  1.135 g/mL at 25 °C

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  44.1
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xn
• 危险类别码：
  R22
• WGK Germany：
  3
• 海关编码：
  2933990090
• 危险性防范说明：
  P280,P305+P351+P338
• 危险性描述：
  H302
• 储存条件：
  2-8°C，干燥

SDS

---

Section 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE
Product identifiers
Product name : N-Boc-7-azaindole
Relevant identified uses of the substance or mixture and uses advised against
Identified uses : Laboratory chemicals, Manufacture of substances

---

Section 2. HAZARDS IDENTIFICATION
Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008 [EU-GHS/CLP]
Acute toxicity, Oral (Category 4)
Classification according to EU Directives 67/548/EEC or 1999/45/EC
Harmful if swallowed.
Label elements
Labelling according Regulation (EC) No 1272/2008 [CLP]
Pictogram
Signal word Warning
Hazard statement(s)
H302 Harmful if swallowed.
Precautionary statement(s) none
Supplemental Hazard none
Statements
According to European Directive 67/548/EEC as amended.
Hazard symbol(s)
R-phrase(s)
R22 Harmful if swallowed.
S-phrase(s) none
Other hazards - none

---

Section 3. COMPOSITION/INFORMATION ON INGREDIENTS
Substances
Synonyms : 1-(tert-Butoxycarbonyl)-1H-pyrrolo[2,3-b]pyridine
1-(tert-Butoxycarbonyl)-7-azaindole
Formula : C12H14N2O2
Molecular Weight : 218,25 g/mol
Component Concentration
N-Boc-7-azaindole
-

---

Section 4. FIRST AID MEASURES
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Consult a physician.
In case of eye contact
Flush eyes with water as a precaution.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
Most important symptoms and effects, both acute and delayed
To the best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly
investigated.
Indication of any immediate medical attention and special treatment needed
no data available

---

Section 5. FIRE-FIGHTING MEASURES
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Carbon oxides, nitrogen oxides (NOx)
Advice for firefighters
Wear self contained breathing apparatus for fire fighting if necessary.
Further information
no data available

---

Section 6. ACCIDENTAL RELEASE MEASURES
Personal precautions, protective equipment and emergency procedures
Use personal protective equipment. Avoid dust formation. Avoid breathing vapors, mist or gas. Ensure
adequate ventilation. Avoid breathing dust.
Environmental precautions
Do not let product enter drains.
Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

---

Section 7. HANDLING AND STORAGE
Precautions for safe handling
Avoid contact with skin and eyes. Avoid formation of dust and aerosols.
Provide appropriate exhaust ventilation at places where dust is formed.Normal measures for preventive fire
protection.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Specific end uses
no data available

---

Section 8. EXPOSURE CONTROLS/PERSONAL PROTECTION
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and at
the end of workday.
Personal protective equipment
Eye/face protection
Safety glasses with side-shields conforming to EN166 Use equipment for eye protection tested and
approved under appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and the
standard EN 374 derived from it.
Body Protection
Complete suit protecting against chemicals, The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
For nuisance exposures use type P95 (US) or type P1 (EU EN 143) particle respirator.For higher
level protection use type OV/AG/P99 (US) or type ABEK-P2 (EU EN 143) respirator cartridges. Use
respirators and components tested and approved under appropriate government standards such as
NIOSH (US) or CEN (EU).

---

Section 9. PHYSICAL AND CHEMICAL PROPERTIES
Information on basic physical and chemical properties
a) Appearance Form: solid
Colour: light yellow
b) Odour no data available
c) Odour Threshold no data available
d) pH no data available
e) Melting point/freezing no data available
point
f) Initial boiling point and no data available
boiling range
g) Flash point no data available
h) Evaporation rate no data available
i) Flammability (solid, gas) no data available
j) Upper/lower no data available
flammability or
explosive limits
k) Vapour pressure no data available
l) Vapour density no data available
m) Relative density 1,135 g/mL at 25 °C
n) Water solubility no data available
o) Partition coefficient: n- log Pow: 2,682
octanol/water
p) Autoignition no data available
temperature
q) Decomposition no data available
temperature
r) Viscosity no data available
s) Explosive properties no data available
t) Oxidizing properties no data available
Other safety information
no data available

---

Section 10. STABILITY AND REACTIVITY
Reactivity
no data available
Chemical stability
no data available
Possibility of hazardous reactions
no data available
Conditions to avoid
no data available
Incompatible materials
Strong oxidizing agents
Hazardous decomposition products
Other decomposition products - no data available

---

Section 11. TOXICOLOGICAL INFORMATION
Information on toxicological effects
Acute toxicity
no data available
Skin corrosion/irritation
no data available
Serious eye damage/eye irritation
no data available
Respiratory or skin sensitization
The preceding data, or interpretation of data, was determined using Quantitative Structure Activity
Relationship (QSAR) modeling.
Germ cell mutagenicity
no data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
no data available
Specific target organ toxicity - single exposure
no data available
Specific target organ toxicity - repeated exposure
no data available
Aspiration hazard
no data available
Potential health effects
Inhalation May be harmful if inhaled. May cause respiratory tract irritation.
Ingestion Harmful if swallowed.
Skin May be harmful if absorbed through skin. May cause skin irritation.
Eyes
May cause eye irritation.
Signs and Symptoms of Exposure
To the best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly
investigated.
Additional Information
RTECS: Not available

---

Section 12. ECOLOGICAL INFORMATION
Toxicity
no data available
Persistence and degradability
no data available
Bioaccumulative potential
no data available
Mobility in soil
no data available
Results of PBT and vPvB assessment
no data available
Other adverse effects
no data available

---

Section 13. DISPOSAL CONSIDERATIONS
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Contact a licensed professional
waste disposal service to dispose of this material. Dissolve or mix the material with a combustible solvent
and burn in a chemical incinerator equipped with an afterburner and scrubber.
Contaminated packaging
Dispose of as unused product.

---

Section 14. TRANSPORT INFORMATION
UN number
ADR/RID: - IMDG: - IATA: -
UN proper shipping name
ADR/RID: Not dangerous goods
IMDG: Not dangerous goods
IATA: Not dangerous goods
Transport hazard class(es)
ADR/RID: - IMDG: - IATA: -
Packaging group
ADR/RID: - IMDG: - IATA: -
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
no data available

---

---

SECTION 15 - REGULATORY INFORMATION
N/A

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1-Boc-7-氮杂吲哚 在 potassium phosphate 作用下， 以 甲醇 为溶剂， 120.0 ℃ 、689.49 kPa 条件下， 反应 0.03h， 以98%的产率得到7-氮杂吲哚
  参考文献：
  名称：

  在甲醇中使用K 3 PO 4 ·H 2 O在温和的碱性条件下进行微波辅助的N - Boc脱保护

  摘要：

  提出了一种简单有效的方法，在中等碱性条件下，采用K 3 PO 4 ·H 2 O的MeOH溶液，通过微波辐照，在Boc保护的仲氨基化合物上进行脱保护。

  DOI：

  10.1016/j.tetlet.2008.12.074
• 作为产物：
  描述：

  2-氨基-3-甲基吡啶 在 仲丁基锂 、 甲基磺酰氯 、 三乙胺 、 N,N-二甲基甲酰胺 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 0.08h， 生成 1-Boc-7-氮杂吲哚
  参考文献：
  名称：

  Preparation of Indoles and Oxindoles fromN-(tert-Butoxycarbonyl)-2-alkylanilines

  摘要：

  使用双锂化的N-(叔丁氧羰基)苯胺1与二甲基甲酰胺或二氧化碳反应，可得到中间体3和5，它们分别容易转化为N-(叔丁氧羰基)吲哚4和氧化吲哚（吲哚-2(3H)-酮，7）。双锂化的1与N-甲氧基-N-甲基酰胺缩合得到酮9，这些酮在三氟乙酸处理下环化，根据反应时间的不同，形成2-取代的1-(叔丁氧羰基)吲哚10或2-取代的吲哚11。这一通用方法已被应用于高效合成1,2-烷基桥联吲哚12、1,3,4,5-四氢苯[c,d]吲哚（16）、2a,3,4,5-四氢苯[c,d]吲哚-2(1H)-酮（18）以及1-(叔丁氧羰基)-1H-吡咯并[2,3-b]吡啶（21）。

  DOI：

  10.1055/s-1991-26597

文献信息

• Microwave-Accelerated Iridium-Catalyzed Borylation of Aromatic C−H Bonds
  作者：Peter Harrisson、James Morris、Todd B. Marder、Patrick G. Steel

  DOI：10.1021/ol901306m

  日期：2009.8.20

  accelerates the Ir-catalyzed C−H borylation of aromatic substrates when compared with reactions carried out at the same temperature under standard heating conditions. Application to a one-pot single solvent process for tandem C−H borylation/Suzuki−Miyaura cross-coupling sequences using microwave-accelerated reactions gives fast and efficient access to a wide range of biaryl and heterobiaryl compounds.

  与在标准加热条件下在相同温度下进行的反应相比，微波加热可加速芳族底物的Ir催化CH硼化。通过微波加速反应应用于串联C–H硼酸酯化/ Suzuki-Miyaura交叉偶联序列的一锅单一溶剂工艺，可以快速，有效地获得各种联芳基和杂联芳基化合物。
• [EN] HETEROCYCLIC MOLECULES AS APOPTOSIS INDUCERS<br/>[FR] MOLÉCULES HÉTÉROCYCLIQUES EN TANT QU'INDUCTEURS D'APOPTOSE
  申请人：BETA PHARMA CANADA INC

  公开号：WO2013053045A1

  公开（公告）日：2013-04-18

  The present document describes novel compounds which may inhibit the activity of anti-apoptotic proteins such as Bcl-2 family protein members, compositions containing the compounds and methods of treating diseases involving a defect in apoptosis, such as, for example, in the treatment of cancer.

  本文件描述了可能抑制抗凋亡蛋白（如Bcl-2家族蛋白成员）活性的新型化合物，包含这些化合物的组合物以及治疗涉及凋亡缺陷的疾病的方法，例如，例如在癌症治疗中。
• [EN] 3-(1H-PYRROLO[2,3-B]PYRIDIN-2-YL)-1H-PYRAZOLO[4,3-B]PYRIDINES AND THERAPEUTIC USES THEREOF<br/>[FR] 3-(1H-PYRROLO[2,3-B]PYRIDIN-2-YL)-1H-PYRAZOLO[4,3-B]PYRIDINES ET LEURS UTILISATIONS THÉRAPEUTIQUES
  申请人：SAMUMED LLC

  公开号：WO2017024004A1

  公开（公告）日：2017-02-09

  4-Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of a 4-azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

  4-氮杂吲唑化合物用于治疗各种疾病和病理已被披露。更具体地，本公开涉及使用4-氮杂吲唑化合物或其类似物，治疗通过Wnt途径信号激活所特征化的疾病（例如，癌症，异常细胞增殖，血管生成，纤维化疾病，骨骼或软骨疾病和骨关节炎），调节由Wnt途径信号介导的细胞事件，以及由于Wnt途径和/或一个或多个Wnt信号组分的突变或失调而导致的遗传疾病和神经病理条件/障碍/疾病。还提供了治疗与Wnt相关疾病状态的方法。
• [EN] SIBIRILINE DERIVATIVES FOR USE FOR PREVENTING AND/OR TREATING DISORDERS ASSOCIATED WITH CELLULAR NECROPTOSIS<br/>[FR] DÉRIVÉS DE SIBIRILINE DESTINÉS À ÊTRE UTILISÉS DANS LA PRÉVENTION ET/OU LE TRAITEMENT DES TROUBLES ASSOCIÉS À LA NÉCROPTOSE CELLULAIRE
  申请人：INST NAT DE LA SANTE ET DE LA RECH MEDICALE (INSERM)

  公开号：WO2017064217A1

  公开（公告）日：2017-04-20

  The present invention relates to a compound of the following general formula (I) or a pharmaceutically acceptable salt and/or solvate thereof, for use as inhibitor of cellular necroptosis. The present invention also relates to a pharmaceutical composition comprising a compound of general formula (I), or a pharmaceutically acceptable salt and/or solvate thereof, for use for preventing and/or treating disorders associated with cellular necroptosis. The present invention also encompasses the use of a compound of the general formula (I) for organs preservation.

  本发明涉及以下一般式（I）的化合物或其药学上可接受的盐和/或溶剂，用作细胞坏死的抑制剂。本发明还涉及包含一般式（I）的化合物或其药学上可接受的盐和/或溶剂的药物组合物，用于预防和/或治疗与细胞坏死相关的疾病。本发明还包括一般式（I）的化合物用于器官保存的用途。
• [EN] 3-(1H-PYRROLO[2,3-B]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINES AND THERAPEUTIC USES THEREOF<br/>[FR] 3-(1H-PYRROLO[2,3-B]PYRIDIN-2-YL)-1H-PYRAZOLO[3,4-C]PYRIDINES ET LEURS UTILISATIONS THÉRAPEUTIQUES
  申请人：SAMUMED LLC

  公开号：WO2017023980A1

  公开（公告）日：2017-02-09

  6-Azaindazole compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of a 6-azaindazole compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis, fibrotic disorders, bone or cartilage diseases, and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

  披露了用于治疗各种疾病和病理的6-氮杂吲唑化合物。更具体地，本公开涉及使用6-氮杂吲唑化合物或其类似物，治疗由Wnt途径信号激活所特征的疾病（例如癌症、异常细胞增殖、血管生成、纤维化疾病、骨骼或软骨疾病和骨关节炎），调节由Wnt途径信号介导的细胞事件，以及由于Wnt途径和/或一个或多个Wnt信号组分的突变或失调而导致的遗传疾病和神经病理条件/障碍/疾病。还提供了治疗与Wnt相关疾病状态的方法。